Guggenheim Maintains Buy on Genmab, Raises Price Target to $42
Genmab A/S
Genmab A/S GMAB | 0.00 |
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:
GMAB) with a Buy and raises the price target from $40 to $42.
Guggenheim Maintains Buy on Genmab, Raises Price Target to $42
Genmab A/S GMAB | 0.00 |